Type 2 Diabetes is a mass-market chronic disease defined by an 8.7M undiagnosed pool and a complication cascade (CKD, cardiovascular, retinopathy) that now anchors drug-class selection.
Type 2 Diabetes Mellitus is a progressive disorder of insulin resistance and beta-cell decline, accounting for 90–95% of the 38.4 million US adults with diabetes (11.6% of the population) per the CDC National Diabetes Statistics Report. Of these, 29.7 million are diagnosed and 8.7 million (22.8% of all cases) remain undiagnosed, while 97.6 million adults (38.0%) carry prediabetes, defining the upstream conversion funnel. Diagnosis rests on the ADA thresholds of A1c ≥6.5%, fasting plasma glucose ≥126 mg/dL, or a two-hour OGTT ≥200 mg/dL.
The commercial centre of gravity has shifted from glycaemic control to complication prevention. Approximately 1 in 3 adults with diabetes has chronic kidney disease, and diabetes remains the leading cause of kidney failure, adult-onset blindness, and non-traumatic lower-limb amputation. This complication burden (and the cardiovascular outcome data behind it) is why the treatment pathway now sequences metformin into SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 receptor agonists (semaglutide, tirzepatide) for organ protection rather than A1c alone. The total US cost of diabetes reached $412.9 billion in 2022, one of every four US healthcare dollars.
US Type 2 Diabetes epidemiology & burden — 2024
| Segment | US Estimate | Basis / Definition | Commercial Implication |
|---|---|---|---|
| Total diabetes prevalence | 38.4M (11.6% of population) | CDC National Diabetes Statistics Report | Mass-market chronic pool; Type 2 is the commercial centre |
| Diagnosed | 29.7M | CDC — receiving or eligible for treatment | Addressable treated-prevalent pool |
| Undiagnosed | 8.7M (22.8% of cases) | CDC — meets criteria, not yet diagnosed | Case-finding and screening opportunity |
| Type 2 share | 90–95% of all diabetes | CDC / ADA | T2D dominates the drug-treated population |
| Prediabetes | 97.6M adults (38.0%) | CDC — A1c 5.7–6.4% / IFG | Upstream conversion funnel; prevention interest |
| CKD in diabetes | ~1 in 3 adults with diabetes | CDC — leading cause of kidney failure | SGLT2 / GLP-1 renal-protection rationale |
| Annual cost burden | $412.9B total US (2022) | ADA, Diabetes Care 2024 | 1 in 4 US healthcare dollars; payer pressure |
Sources: CDC National Diabetes Statistics Report (2021 data cycle); American Diabetes Association, Economic Costs of Diabetes in the U.S. in 2022, Diabetes Care 2024; ADA Standards of Care in Diabetes (diagnostic thresholds).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Diagnosed vs undiagnosed split
- prediabetes conversion funnel (97.6M adults)
- age, comorbidity, and payer-mix segmentation of the treated-prevalent pool
- case-finding opportunity sizing
Delivers
- Complication prevalence within the T2D pool
- organ-protection evidence mapping (renal, heart-failure, MACE)
- treatment-pathway decision points where CVOT/renal data override A1c-only sequencing
Delivers
- Line-of-therapy map (metformin → SGLT2/DPP-4 → GLP-1/GIP-GLP-1 → insulin)
- guideline-driven switch triggers
- oral vs injectable route dynamics and the addressable pool at each step
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Why Type 2 accounts for 90-95% of the 38.4 million US adults with diabetes, per the CDC National Diabetes Statistics Report
- The ADA diagnostic thresholds (A1c >=6.5%, fasting plasma glucose >=126 mg/dL, or two-hour OGTT >=200 mg/dL) that define progression to clinical diabetes
- The split between 29.7 million diagnosed and 8.7 million undiagnosed adults (22.8% of all cases), per the CDC
- The 97.6 million adults (38.0%) with prediabetes who define the upstream conversion funnel into Type 2
- How the ADA's A1c, fasting glucose, and OGTT thresholds gate a formal Type 2 diagnosis
- Where the 8.7 million undiagnosed adults sit relative to the case-finding and screening opportunity
- Why roughly 1 in 3 adults with diabetes has chronic kidney disease, and diabetes remains the leading cause of kidney failure, blindness, and amputation
- How this complication burden is shifting the treatment pathway from A1c control alone toward organ-protective SGLT2 and GLP-1 therapy
- The sequencing from metformin into SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 receptor agonists (semaglutide, tirzepatide)
- Why organ protection, not A1c alone, now drives the guideline-recommended line-of-therapy escalation
- The $412.9 billion total US cost of diabetes in 2022, one of every four US healthcare dollars, per the ADA
- How the diagnosed, undiagnosed, and prediabetic segments each carry a distinct cost and intervention profile
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources (FDA, ClinicalTrials.gov), peer-reviewed literature, and official surveillance data — not secondary summaries. No market research reports or unverified estimates are used. Findings are independently verified before inclusion.
US Type 2 Diabetes Disease Landscape sources: CDC National Diabetes Statistics Report for prevalence and complication data, American Diabetes Association Standards of Care for diagnostic criteria and treatment sequence, ADA Economic Costs of Diabetes (Diabetes Care 2024) for cost burden, and primary cardiovascular and renal outcome trial publications for organ-protection evidence.
- Prevalence, diagnosed vs undiagnosed, and prediabetes figures verified against the CDC National Diabetes Statistics Report
- Complication burden (CKD ~1 in 3; leading cause of kidney failure, blindness, amputation) verified against CDC diabetes surveillance data
- Total US cost of diabetes ($412.9B, 2022) verified against ADA, Economic Costs of Diabetes in the U.S. in 2022, Diabetes Care 2024
- Diagnostic thresholds (A1c ≥6.5%, FPG ≥126, OGTT ≥200) verified against ADA Standards of Care in Diabetes
Frequently asked questions
Commission this assessment
AXLRx US Type 2 Diabetes Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the US T2D patient population. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.